Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine and Oxybutynin in Obstructive Sleep Apnea
NCT02908529Phase 2Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Sep 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atomoxetine and oxybutynin in obstructive sleep apnea (OSA) (2 arms), sponsored by Brigham and Women's Hospital. Primary endpoint: Apnea Hypopnea Index. Started Sep 2016; status: completed.
02
Drugs
atomoxetineoxybutynin
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT02908529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02908529.